EPISODE · Mar 6, 2019 · 18 MIN
A Different Approach to Inhibiting the Complement System
from RARECast
The complement system, part of the immune system, has long been used as a target for interventions in certain rare disease. Apellis Pharmaceuticals is developing therapies to treat rare blood and kidney diseases, but by targeting a different part of the complement system than available therapies do today. We spoke to Cedric Francois, co-founder, president and CEO of Apellis, about the complement system, Apellis’ approach, and why he thinks this will lead to better therapies for these rare diseases.
What this episode covers
The complement system, part of the immune system, has long been used as a target for interventions in certain rare disease. Apellis Pharmaceuticals is developing therapies to treat rare blood and kidney diseases, but by targeting a different part of the complement system than available therapies do today. We spoke to Cedric Francois, co-founder, president and CEO of Apellis, about the complement system, Apellis’ approach, and why he thinks this will lead to better therapies for these rare diseases.
NOW PLAYING
A Different Approach to Inhibiting the Complement System
No transcript for this episode yet
Similar Episodes
Feb 14, 2021 ·32m
Feb 13, 2021 ·98m
Sep 4, 2020 ·5m